Intellectual Property India Publishes Patent Application for 'Dnase 1-Like 3 Engineered For Improved Expression And Use In Therapy' Filed by Neutrolis, Inc.

MUMBAI, India, July 5 -- Intellectual Property India has published a patent application (202517055940 A) filed by Neutrolis, Inc., Cambridge, U.S.A., on June 10, for 'dnase 1-like 3 engineered for improved expression and use in therapy.'

Inventor(s) include Fox, Tobias, A.

The application for the patent was published on July 4, under issue no. 27/2025.

According to the abstract released by the Intellectual Property India: "The present disclosure provides methods for engineering proteins (e.g., DNase enzymes) for improved production, structural homogeneity, and/or reduced immunity."

The patent application was internationally filed on Nov. 14, 2023, under International application No.PCT/US2023/079602.

Disclaimer: Curated by HT Syndication.